Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy
Barium ferrite nanoparticles (BaFeNPs) were investigated as vehicles for <sup>223</sup>Ra radionuclide in targeted α-therapy. BaFe nanoparticles were labeled using a hydrothermal Ba<sup>2+</sup> cations replacement by <sup>223</sup>Ra with yield reaching 61.3 ± 1....
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Nanomaterials |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-4991/10/10/2067 |
id |
doaj-e5b1ab7c4e4d48a585d422d27ca7575b |
---|---|
record_format |
Article |
spelling |
doaj-e5b1ab7c4e4d48a585d422d27ca7575b2020-11-25T03:44:29ZengMDPI AGNanomaterials2079-49912020-10-01102067206710.3390/nano10102067Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha RadioimmunotherapyWeronika Gawęda0Marek Pruszyński1Edyta Cędrowska2Magdalena Rodak3Agnieszka Majkowska-Pilip4Damian Gaweł5Frank Bruchertseifer6Alfred Morgenstern7Aleksander Bilewicz8Institute of Nuclear Chemistry and Technology, Dorodna 16 Str., 03-195 Warsaw, PolandInstitute of Nuclear Chemistry and Technology, Dorodna 16 Str., 03-195 Warsaw, PolandInstitute of Nuclear Chemistry and Technology, Dorodna 16 Str., 03-195 Warsaw, PolandInstitute of Nuclear Chemistry and Technology, Dorodna 16 Str., 03-195 Warsaw, PolandInstitute of Nuclear Chemistry and Technology, Dorodna 16 Str., 03-195 Warsaw, PolandDepartment of Immunohematology, Centre of Postgraduate Medical Education, Marymoncka 99/103, 01-813 Warsaw, PolandEuropean Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, 76125 Karlsruhe, GermanyEuropean Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, 76125 Karlsruhe, GermanyInstitute of Nuclear Chemistry and Technology, Dorodna 16 Str., 03-195 Warsaw, PolandBarium ferrite nanoparticles (BaFeNPs) were investigated as vehicles for <sup>223</sup>Ra radionuclide in targeted α-therapy. BaFe nanoparticles were labeled using a hydrothermal Ba<sup>2+</sup> cations replacement by <sup>223</sup>Ra with yield reaching 61.3 ± 1.8%. Radiolabeled nanoparticles were functionalized with 3-phosphonopropionic acid (CEPA) linker followed by covalent conjugation to trastuzumab (Herceptin<sup>®</sup>). Thermogravimetric analysis and radiometric method with the use of [<sup>131</sup>I]-labeled trastuzumab revealed that on average 19–21 molecules of trastuzumab are attached to the surface of one BaFe–CEPA nanoparticle. The hydrodynamic diameter of BaFe–CEPA–trastuzumab conjugate is 99.9 ± 3.0 nm in water and increases to 218.3 ± 3.7 nm in PBS buffer, and the zeta potential varies from +27.2 ± 0.7 mV in water to −8.8 ± 0.7 in PBS buffer. The [<sup>223</sup>Ra]BaFe–CEPA–trastuzumab radiobioconjugate almost quantitatively retained <sup>223</sup>Ra (>98%) and about 96% of <sup>211</sup>Bi and 94% of <sup>211</sup>Pb over 30 days. The obtained radiobioconjugate exhibited high affinity, cell internalization and cytotoxicity towards the human ovarian adenocarcinoma SKOV-3 cells overexpressing HER2 receptor. Confocal studies indicated that [<sup>223</sup>Ra]BaFe–CEPA–trastuzumab was located in peri-nuclear space. High cytotoxicity of the [<sup>223</sup>Ra]BaFe–CEPA–trastuzumab bioconjugate was confirmed by radiotoxicity studies on SKOV-3 cell monolayers and 3D-spheroids. In addition, the magnetic properties of the radiobioconjugate should allow for its use in guide drug delivery driven by magnetic field gradient.https://www.mdpi.com/2079-4991/10/10/2067alpha radioimmunotherapyradium-223barium ferrite |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Weronika Gawęda Marek Pruszyński Edyta Cędrowska Magdalena Rodak Agnieszka Majkowska-Pilip Damian Gaweł Frank Bruchertseifer Alfred Morgenstern Aleksander Bilewicz |
spellingShingle |
Weronika Gawęda Marek Pruszyński Edyta Cędrowska Magdalena Rodak Agnieszka Majkowska-Pilip Damian Gaweł Frank Bruchertseifer Alfred Morgenstern Aleksander Bilewicz Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy Nanomaterials alpha radioimmunotherapy radium-223 barium ferrite |
author_facet |
Weronika Gawęda Marek Pruszyński Edyta Cędrowska Magdalena Rodak Agnieszka Majkowska-Pilip Damian Gaweł Frank Bruchertseifer Alfred Morgenstern Aleksander Bilewicz |
author_sort |
Weronika Gawęda |
title |
Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy |
title_short |
Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy |
title_full |
Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy |
title_fullStr |
Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy |
title_full_unstemmed |
Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy |
title_sort |
trastuzumab modified barium ferrite magnetic nanoparticles labeled with radium-223: a new potential radiobioconjugate for alpha radioimmunotherapy |
publisher |
MDPI AG |
series |
Nanomaterials |
issn |
2079-4991 |
publishDate |
2020-10-01 |
description |
Barium ferrite nanoparticles (BaFeNPs) were investigated as vehicles for <sup>223</sup>Ra radionuclide in targeted α-therapy. BaFe nanoparticles were labeled using a hydrothermal Ba<sup>2+</sup> cations replacement by <sup>223</sup>Ra with yield reaching 61.3 ± 1.8%. Radiolabeled nanoparticles were functionalized with 3-phosphonopropionic acid (CEPA) linker followed by covalent conjugation to trastuzumab (Herceptin<sup>®</sup>). Thermogravimetric analysis and radiometric method with the use of [<sup>131</sup>I]-labeled trastuzumab revealed that on average 19–21 molecules of trastuzumab are attached to the surface of one BaFe–CEPA nanoparticle. The hydrodynamic diameter of BaFe–CEPA–trastuzumab conjugate is 99.9 ± 3.0 nm in water and increases to 218.3 ± 3.7 nm in PBS buffer, and the zeta potential varies from +27.2 ± 0.7 mV in water to −8.8 ± 0.7 in PBS buffer. The [<sup>223</sup>Ra]BaFe–CEPA–trastuzumab radiobioconjugate almost quantitatively retained <sup>223</sup>Ra (>98%) and about 96% of <sup>211</sup>Bi and 94% of <sup>211</sup>Pb over 30 days. The obtained radiobioconjugate exhibited high affinity, cell internalization and cytotoxicity towards the human ovarian adenocarcinoma SKOV-3 cells overexpressing HER2 receptor. Confocal studies indicated that [<sup>223</sup>Ra]BaFe–CEPA–trastuzumab was located in peri-nuclear space. High cytotoxicity of the [<sup>223</sup>Ra]BaFe–CEPA–trastuzumab bioconjugate was confirmed by radiotoxicity studies on SKOV-3 cell monolayers and 3D-spheroids. In addition, the magnetic properties of the radiobioconjugate should allow for its use in guide drug delivery driven by magnetic field gradient. |
topic |
alpha radioimmunotherapy radium-223 barium ferrite |
url |
https://www.mdpi.com/2079-4991/10/10/2067 |
work_keys_str_mv |
AT weronikagaweda trastuzumabmodifiedbariumferritemagneticnanoparticleslabeledwithradium223anewpotentialradiobioconjugateforalpharadioimmunotherapy AT marekpruszynski trastuzumabmodifiedbariumferritemagneticnanoparticleslabeledwithradium223anewpotentialradiobioconjugateforalpharadioimmunotherapy AT edytacedrowska trastuzumabmodifiedbariumferritemagneticnanoparticleslabeledwithradium223anewpotentialradiobioconjugateforalpharadioimmunotherapy AT magdalenarodak trastuzumabmodifiedbariumferritemagneticnanoparticleslabeledwithradium223anewpotentialradiobioconjugateforalpharadioimmunotherapy AT agnieszkamajkowskapilip trastuzumabmodifiedbariumferritemagneticnanoparticleslabeledwithradium223anewpotentialradiobioconjugateforalpharadioimmunotherapy AT damiangaweł trastuzumabmodifiedbariumferritemagneticnanoparticleslabeledwithradium223anewpotentialradiobioconjugateforalpharadioimmunotherapy AT frankbruchertseifer trastuzumabmodifiedbariumferritemagneticnanoparticleslabeledwithradium223anewpotentialradiobioconjugateforalpharadioimmunotherapy AT alfredmorgenstern trastuzumabmodifiedbariumferritemagneticnanoparticleslabeledwithradium223anewpotentialradiobioconjugateforalpharadioimmunotherapy AT aleksanderbilewicz trastuzumabmodifiedbariumferritemagneticnanoparticleslabeledwithradium223anewpotentialradiobioconjugateforalpharadioimmunotherapy |
_version_ |
1724514659732553728 |